Araris Biotech AG

Araris Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, develops novel antibody-drug conjugates for targeted cancer chemotherapy. Araris’ technology allows active substances to bind stably to antibodies, so that the often very aggressive cancer drugs only take effect in the body where they are actually supposed to. Araris’ goal is to make cancer treatment more effective and at the same time gentler for patients.